Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Tuberculosis

  Free Subscription


Articles published in Am J Respir Crit Care Med

Retrieve available abstracts of 65 articles:
HTML format



Single Articles


    February 2024
  1. TREVISI L, Brooks MB, Becerra MC, Calderon RI, et al
    Who Transmits Tuberculosis to Whom: A Cross-Sectional Analysis of a Cohort Study in Lima, Peru.
    Am J Respir Crit Care Med. 2024 Feb 28. doi: 10.1164/rccm.202307-1217.
    PubMed     Abstract available


    October 2023
  2. ANIDI IU, Kirenga B, Fennelly KP
    Pulmonary Rehabilitation for Post-Tuberculosis Lung Disease.
    Am J Respir Crit Care Med. 2023 Oct 5. doi: 10.1164/rccm.202309-1571.
    PubMed    


  3. ROCHESTER CL, Alison JA, Carlin B, Holland AE, et al
    Reply to: Pulmonary Rehabilitation for Post-Tuberculosis Lung Disease.
    Am J Respir Crit Care Med. 2023 Oct 5. doi: 10.1164/rccm.202309-1714.
    PubMed    


    July 2023
  4. OTTEWILL C, Dolan L, Lopez Bailen E, Roycroft E, et al
    Immunosuppressed Pets as a Conduit for Zoonotic Tuberculosis.
    Am J Respir Crit Care Med. 2023 Jul 25. doi: 10.1164/rccm.202304-0734.
    PubMed    


    June 2023
  5. PATANKAR S, Cruz AT, Douglas-Jones B, Garcia-Prats A, et al
    Making the Case for All-Oral, Shorter Regimens for Children with Drug-Resistant Tuberculosis.
    Am J Respir Crit Care Med. 2023 Jun 5. doi: 10.1164/rccm.202304-0670.
    PubMed    


  6. BRUST JCM
    "Weighting" the Evidence: How Much Bedaquiline Is Enough?
    Am J Respir Crit Care Med. 2023;207:1423-1424.
    PubMed    


    May 2023
  7. MITNICK CD, Nunn AJ
    Ascertainment Bias in TB Treatment Trials: Can Systematic Assessment of Objective Endpoints Solve It?
    Am J Respir Crit Care Med. 2023;207:1269-1270.
    PubMed    


  8. KURBATOVA EV, Phillips PPJ, Dorman SE, Sizemore EE, et al
    A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials.
    Am J Respir Crit Care Med. 2023;207:1376-1382.
    PubMed     Abstract available


    April 2023
  9. BORGES DE ALMEIDA CP, Mitnick CD
    Intervening on Social Determinants for Better Outcomes in Pediatric Tuberculosis Management.
    Am J Respir Crit Care Med. 2023 Apr 19. doi: 10.1164/rccm.202303-0601.
    PubMed    


  10. MARTINEZ L, Zar HJ
    Reply to: Intervening on Social Determinants for Better Outcomes in Pediatric Tuberculosis Management.
    Am J Respir Crit Care Med. 2023 Apr 19. doi: 10.1164/rccm.202304-0629.
    PubMed    


  11. MASEKELA R, Mandalakas AM
    Pediatric Post-TB Lung Disease: Ready for Prime Time?
    Am J Respir Crit Care Med. 2023;207:975-977.
    PubMed    


    February 2023
  12. TREVISI L, Hernan MA, Mitnick CD, Khan U, et al
    Effectiveness of Bedaquiline Use Beyond Six Months in Patients with Multidrug-Resistant Tuberculosis.
    Am J Respir Crit Care Med. 2023 Feb 21. doi: 10.1164/rccm.202211-2125.
    PubMed     Abstract available


  13. MARTINEZ L, Gray DM, Botha M, Nel M, et al
    The Long-Term Impact of Early-Life Tuberculosis Disease on Child Health: A Prospective Birth Cohort Study.
    Am J Respir Crit Care Med. 2023 Feb 6. doi: 10.1164/rccm.202208-1543.
    PubMed     Abstract available


    January 2023
  14. STAGG HR, Thompson JA, Lipman MCI, Sloan DJ, et al
    Forgiveness Is the Attribute of the Strong: Nonadherence and Regimen Shortening in Drug-sensitive Tuberculosis.
    Am J Respir Crit Care Med. 2023;207:193-205.
    PubMed     Abstract available


  15. VELASQUEZ GE, Nahid P
    Promise and Peril of Pretomanid-Rifamycin Regimens for Drug-Susceptible Tuberculosis.
    Am J Respir Crit Care Med. 2023 Jan 11. doi: 10.1164/rccm.202212-2262.
    PubMed    


    December 2022
  16. DOOLEY KE, Hendricks B, Gupte N, Barnes G, et al
    Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-containing Regimens for Drug-sensitive TB: 12-Week Results.
    Am J Respir Crit Care Med. 2022 Dec 1. doi: 10.1164/rccm.202208-1475.
    PubMed     Abstract available



  17. Erratum: Response to Hypoxia and the Ensuing Dysregulation of Inflammation Impacts Mycobacterium tuberculosis Pathogenicity.
    Am J Respir Crit Care Med. 2022;206:1434.
    PubMed    


    October 2022
  18. CHECKLEY W
    Tuberculosis, Wildfires, and Case-Crossover Studies: An Epidemiological Trifecta?
    Am J Respir Crit Care Med. 2022 Oct 31. doi: 10.1164/rccm.202210-1936.
    PubMed    


    September 2022

  19. Erratum: Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling.
    Am J Respir Crit Care Med. 2022;206:800-801.
    PubMed    


  20. LINDE LR, Readhead A, Barry PM, Balmes JR, et al
    Tuberculosis Diagnoses Following Wildfire Smoke Exposure in California.
    Am J Respir Crit Care Med. 2022 Sep 14. doi: 10.1164/rccm.202203-0457.
    PubMed     Abstract available


    June 2022
  21. MARAIS BJ, Graham SM
    The Value of Chest Radiography in Tuberculosis Preventive Treatment (TPT) Screening in Children and Adolescents.
    Am J Respir Crit Care Med. 2022 Jun 2. doi: 10.1164/rccm.202205-1023.
    PubMed    


    May 2022
  22. DOWDY DW
    Coughing is Not Required to Transmit Mycobacterium tuberculosis: Another Nail in the Coffin.
    Am J Respir Crit Care Med. 2022 May 25. doi: 10.1164/rccm.202204-0645.
    PubMed    


  23. HUANG CC, Tan Q, Becerra MC, Calderon R, et al
    The Contribution of Chest Radiography to the Clinical Management of Children Exposed to Tuberculosis.
    Am J Respir Crit Care Med. 2022 May 24. doi: 10.1164/rccm.202202-0259.
    PubMed     Abstract available


  24. DINKELE R, Gessner S, McKerry A, Leonard B, et al
    Aerosolization of Mycobacterium tuberculosis by Tidal Breathing.
    Am J Respir Crit Care Med. 2022 May 18. doi: 10.1164/rccm.202110-2378.
    PubMed     Abstract available


  25. DE JAGER V, Gupte N, Nunes S, Barnes GL, et al
    Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial.
    Am J Respir Crit Care Med. 2022;205:1228-1235.
    PubMed     Abstract available


  26. ESMAIL A, Oelofse S, Lombard C, Perumal R, et al
    An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study).
    Am J Respir Crit Care Med. 2022;205:1214-1227.
    PubMed     Abstract available


    April 2022
  27. SHAKU MT, Bishai WR
    Mycobacterium tuberculosis: A Pathogen That Can Hold its Breath a Long Time.
    Am J Respir Crit Care Med. 2022 Apr 20. doi: 10.1164/rccm.202203-0432.
    PubMed    


  28. BUCSAN AN, Veatch A, Singh DK, Akter S, et al
    Response to Hypoxia and the Ensuing Dysregulation of Inflammation Impacts Mycobacterium tuberculosis Pathogenicity.
    Am J Respir Crit Care Med. 2022 Apr 12. doi: 10.1164/rccm.202112-2747.
    PubMed     Abstract available


  29. PITTET LF, Fritschi N, Tebruegge M, Dutta B, et al
    Bacillus Calmette-Guerin Skin Reaction Predicts Enhanced Mycobacteria-Specific T-Cell Responses in Infants: A Post Hoc Analysis of a Randomized Controlled Trial.
    Am J Respir Crit Care Med. 2022;205:830-841.
    PubMed     Abstract available


    March 2022
  30. LANGE C, Barry Iii CE, Horsburgh CR Jr
    Treatments of Multidrug-Resistant Tuberculosis: Light at the End of the Tunnel.
    Am J Respir Crit Care Med. 2022 Mar 23. doi: 10.1164/rccm.202202-0393.
    PubMed    


    January 2022
  31. SCHLUGER NW
    Of Mice and Men, Women, and Children: Using Animal Models to Inform Tuberculosis Clinical Trials of Novel Agents.
    Am J Respir Crit Care Med. 2022 Jan 31. doi: 10.1164/rccm.202112-2866.
    PubMed    


  32. O'DONNELL M, Mathema B
    Expanding the Tuberculosis Cascade of Care to Treat Undiagnosed and Subclinical Tuberculosis in High-Burden Settings.
    Am J Respir Crit Care Med. 2022;205:149-151.
    PubMed    


    December 2021
  33. KAUSHIK A, Ammerman NC, Tasneen R, Lachau-Durand S, et al
    Efficacy of Long-Acting Bedaquiline Regimens in a Mouse Model of Tuberculosis Preventive Therapy.
    Am J Respir Crit Care Med. 2021 Dec 23. doi: 10.1164/rccm.202012-4541.
    PubMed     Abstract available


  34. FENNELLY KP, Martinez L, Mandalakas AM
    Tuberculosis: First in Flight.
    Am J Respir Crit Care Med. 2021 Dec 14. doi: 10.1164/rccm.202111-2513.
    PubMed    


  35. SHIMIZU T, Watanabe S, Murata A, Kasahara K, et al
    Bronchial Cast Hiding Pulmonary Tuberculosis.
    Am J Respir Crit Care Med. 2021 Dec 3. doi: 10.1164/rccm.202105-1306.
    PubMed    


  36. SCHLUGER NW
    Using Isoniazid More Safely and More Effectively: The Time Is Now.
    Am J Respir Crit Care Med. 2021;204:1248-1250.
    PubMed    


    November 2021
  37. BUNYASI EW, Middelkoop K, Koch A, Hoosen Z, et al
    Molecular Detection of Airborne Mycobacterium tuberculosis in South African High Schools.
    Am J Respir Crit Care Med. 2021 Nov 9. doi: 10.1164/rccm.202102-0405.
    PubMed     Abstract available


  38. ADJOBIMEY M, Behr MA, Menzies D
    Individualized Treatment Duration in Tuberculosis Treatment: Precision versus Simplicity.
    Am J Respir Crit Care Med. 2021;204:1013-1014.
    PubMed    


    October 2021
  39. ATRE SR, Jagtap JD, Faqih MI, Dumbare YK, et al
    Tuberculosis Pathways to Care and Transmission of Multidrug-Resistance in India.
    Am J Respir Crit Care Med. 2021 Oct 27. doi: 10.1164/rccm.202012-4333.
    PubMed     Abstract available


  40. NOURSADEGHI M, Gupta RK
    New Insights into the Limitations of Host-Transcriptional Biomarkers of Tuberculosis.
    Am J Respir Crit Care Med. 2021 Oct 27. doi: 10.1164/rccm.202109-2146.
    PubMed    


    September 2021
  41. MULENGA H, Musvosvi M, Mendelsohn SC, Penn-Nicholson A, et al
    Longitudinal Dynamics of a Blood Transcriptomic Signature of Tuberculosis.
    Am J Respir Crit Care Med. 2021 Sep 14. doi: 10.1164/rccm.202103-0548.
    PubMed     Abstract available


  42. DARTOIS V, Dick T
    A Ginger Root or Plum Model for the Tuberculosis "Granuloma"?
    Am J Respir Crit Care Med. 2021;204:505-507.
    PubMed    


    August 2021
  43. DAVIS JL, Checkley W
    Characterization of Air Pollution Exposures as Risk Factors for Tuberculosis Infection.
    Am J Respir Crit Care Med. 2021 Aug 30. doi: 10.1164/rccm.202107-1795.
    PubMed    


  44. GAUSI K, Ignatius EH, Sun X, Kim S, et al
    A Semi-Mechanistic Model of the Bactericidal Activity of High-Dose Isoniazid Against Multi-Drug-Resistant Tuberculosis: Results from a Randomized Clinical Trial.
    Am J Respir Crit Care Med. 2021 Aug 17. doi: 10.1164/rccm.202103-0534.
    PubMed     Abstract available


  45. MITNICK CD, Furin JJ, Hewison C
    The Reductionist Conundrum of an "Updated" Definition of Extensively Drug-resistant Tuberculosis.
    Am J Respir Crit Care Med. 2021 Aug 10. doi: 10.1164/rccm.202106-1516.
    PubMed    


  46. VERMA R, Patil S, Zhang N, Moreira FMF, et al
    A Rapid Pharmacogenomic Assay to Detect NAT2 Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment.
    Am J Respir Crit Care Med. 2021 Aug 10. doi: 10.1164/rccm.202103-0564.
    PubMed     Abstract available


  47. IMPERIAL MZ, Phillips PPJ, Nahid P, Savic RM, et al
    Precision-enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials.
    Am J Respir Crit Care Med. 2021 Aug 4. doi: 10.1164/rccm.202101-0117.
    PubMed     Abstract available


  48. BLOUNT RJ, Phan H, Trinh T, Dang H, et al
    Indoor Air Pollution and Susceptibility to Tuberculosis Infection in Urban Vietnamese Children.
    Am J Respir Crit Care Med. 2021 Aug 3. doi: 10.1164/rccm.202101-0136.
    PubMed     Abstract available


    June 2021
  49. ROELENS M, Battista Migliori G, Rozanova L, Estill J, et al
    Evidence-based Definition for Extensively Drug-resistant Tuberculosis.
    Am J Respir Crit Care Med. 2021 Jun 9. doi: 10.1164/rccm.202009-3527.
    PubMed     Abstract available


    May 2021
  50. WELLS G, Glasgow JN, Nargan K, Lumamba K, et al
    microCT Analysis of the Human Tuberculous Lung Reveals Remarkable Heterogeneity in 3D Granuloma Morphology.
    Am J Respir Crit Care Med. 2021 May 20. doi: 10.1164/rccm.202101-0032.
    PubMed     Abstract available


    April 2021

  51. Retraction: Isoniazid and Rifapentine Treatment Eradicates Persistent Mycobacterium tuberculosis in Macaques.
    Am J Respir Crit Care Med. 2021;203:1045.
    PubMed    


  52. HUDDART S, Savic RM, Cattamanchi A
    Is Glycemic Control the Secret to Tuberculosis Control?
    Am J Respir Crit Care Med. 2021 Apr 7. doi: 10.1164/rccm.202103-0703.
    PubMed    


    March 2021
  53. BEHR MA, Kaufmann E, Duffin J, Edelstein PH, et al
    Latent Tuberculosis: Two Centuries of Confusion.
    Am J Respir Crit Care Med. 2021 Mar 24. doi: 10.1164/rccm.202011-4239.
    PubMed     Abstract available


  54. LIU Q, You N, Pan H, Shen Y, et al
    Glycemic Trajectories After Tuberculosis Diagnosis and Treatment Outcomes of New Tuberculosis Patients: A Prospective Study in Eastern China.
    Am J Respir Crit Care Med. 2021 Mar 11. doi: 10.1164/rccm.202007-2634.
    PubMed     Abstract available


  55. KENDALL EA, Shrestha S, Dowdy DW
    Reply to: Subclinical Tuberculosis: Some Flies in the Ointment.
    Am J Respir Crit Care Med. 2021 Mar 9. doi: 10.1164/rccm.202102-0367.
    PubMed    


  56. PIERCE CW
    Subclinical Tuberculosis: Some Flies in the Ointment.
    Am J Respir Crit Care Med. 2021 Mar 9. doi: 10.1164/rccm.202101-0227.
    PubMed    


  57. LE ROUX SP, Upton C, Vanker N, Dooley KE, et al
    Resistance-Conferring Mycobacterial Mutations and Quantification of Early Bactericidal Activity.
    Am J Respir Crit Care Med. 2021;203:635-637.
    PubMed    


    February 2021
  58. ESCALANTE P, Wilson JW
    New Diagnostics to Infer Risk in Tuberculosis: Is the Term Latent Tuberculosis Infection Obsolete?
    Am J Respir Crit Care Med. 2021 Feb 17. doi: 10.1164/rccm.202101-0131.
    PubMed    


    January 2021
  59. MPANDE CAM, Musvosvi M, Rozot V, Mosito B, et al
    Antigen-specific T Cell Activation Distinguishes Between Recent and Remote Tuberculosis Infection.
    Am J Respir Crit Care Med. 2021 Jan 6. doi: 10.1164/rccm.202007-2686.
    PubMed     Abstract available


  60. FRANKE MF, Khan P, Hewison C, Khan U, et al
    Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study.
    Am J Respir Crit Care Med. 2021;203:111-119.
    PubMed     Abstract available


    December 2020
  61. HOSODA C, Ishiguro T, Shimizu Y, Kanegane H, et al
    Mycobacterium genavense Infection Presenting as an Endobronchial Polyp and Upper Lobe Atelectasis.
    Am J Respir Crit Care Med. 2020;202:e144-e145.
    PubMed    


    November 2020
  62. KENDALL EA, Shrestha S, Dowdy DW
    The Epidemiological Importance of Subclinical Tuberculosis: A Critical Re-Appraisal.
    Am J Respir Crit Care Med. 2020 Nov 16. doi: 10.1164/rccm.202006-2394.
    PubMed     Abstract available


    September 2020
  63. CHANG KC, Yew WW
    ATS/CDC/ERS/IDSA Clinical Practice Guidelines for Treatment of Drug-Resistant Tuberculosis: A Two-edged Sword?
    Am J Respir Crit Care Med. 2020;202:777-778.
    PubMed    


  64. SOTGIU G, Battista Migliori G, Menzies D, Mase S, et al
    Reply to Chang and Yew.
    Am J Respir Crit Care Med. 2020;202:778-779.
    PubMed    


    August 2020
  65. DAWRS SN, Kautz M, Chan ED, Honda JR, et al
    Mycobacterium abscessus and Gastroesophageal Reflux: An In Vitro Study.
    Am J Respir Crit Care Med. 2020;202:466-469.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.